EMEA-002146-PIP01-17-M04
Key facts
| Invented name |
Ibrance
|
| Active substance |
Palbociclib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0117/2022
|
| PIP number |
EMEA-002146-PIP01-17-M04
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of Ewing sarcoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 1304 6466 07 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|